Abstract
Phencyclidine (PCP) is a potent psychotomimetic drug of abuse and has profound effect on the functioning of the central nervous system (CNS). Many of the CNS functions are known to be mediated by calcium (Ca2+). In the present study we have investigated the effects of PCP on Ca2+ ATPase activity in rat brain both in vitro and in vivo. For in vitro studies, synaptic membrane fractions prepared from normal rat brain were incubated with PCP at different concentrations (25-100 μM) before the addition of substrate. For n vivo studies, rats were treated with a single moderate dose of PCP (10 mg/kg, IP) and animals were sacrificed at 1,2, 6 and 12 h after treatment. Ca2+ ATPase activity in synaptic membrane fractions was assayed by estimation of inorganic phosphate. PCP inhibited the Ca2+ ATPase in vitro in a concentration dependent manner with significant effect at 50 and 100 μM. A significant time-dependent reduction of the Ca2+ ATPase activity was evident in vivo. As early as 2 h after the treatment of rats with PCP the ATPase activity was significantly reduced. The reduction of Ca2+ ATPase observed even at 12 h after treatment suggesting a prolonged presence of the drug in the brain tissue. Further, kinetic studies in vitro indicated PCP to be a competitive inhibitor of Ca2+ ATPase with respect to the substrate, ATP. The present findings indicate that PCP inhibits synaptic membrane Ca2+ ATPase thus altering cellular Ca2+ homeostasis in CNS which may partially explain the pharmacological effects of the drug and/or its neurotoxicity.
Similar content being viewed by others
References
Aniline O, Simpson GM: Psychiatric aspects of phencyclidine. In: L. Manzo (ed). Advances In Neurotoxicology. Pergman Press, New York, 1979, pp 27–30
Albuquerque EX, Aguayo LG, Warnick JE, Weinstein H, Glick SD, Maayani S, Ickowicz RK, Blaustein MP: The behavioral effects of phencyclidines may be due to their blockade of potassium channels. Proc Natl Acad Sci USA 78: 7792–7796, 1981
Ffrench-Mullen JMH, Rogawski MA: Phencyclidine block of calcium current in isolated guinea pig hippocampal neurons. J Physiol 456: 85–105, 1992
Tourneur Y, Romey G, Lazdunski M: Phencyclidine blockade of sodium and potassium channels in neuroblastoma cells. Brain Res 5: 154–158, 1982
Mattson MP, Rychlik B, Cheng B: Degenerative and axon outgrowth – altering effects of phencyclidine in human fetal cerebral cortical cells. Neuropharmacol 51: 279–291, 1992
Mattson MP, Rychlik B, You JS, Sisken JE: Sensitivity of cultured human embryonic cerebral cortical neurons to excitatory amino acidinduced calcium influx and neurotoxicity. Brain Res 542: 97–106, 1991
Vincent JP, Cavey D, Kamenka JM, Geneste P, Lazdinski M: Interaction of phencyclidine with the muscarinic and opiate receptors in the central nervous system. Brain Res 152: 176–182, 1978
Leonard BE, Tonge SR: Some effect of a hallucinogenic drug (Phencyclidine). Life Sci 9: 1141–1152, 1970
Domino EF, Wilson AE: Psychotropic drug influences on brain acetylcholine utilization. Psychopharmacol 25: 291–298, 1972
Eldefrawi AT, Miller ER, Murphy DL, Eldefrawi MW: [3H]phencyclidine interactions with the nicotonic acetylcholine receptor channel and its inhibition by psychotripic, antipsychotic, opiate, antidepressant, antibiotic and viral and antiarrythmic drugs. Mol Pharmacol 22: 72–81, 1982
Haring R, Kloog Y, Sodolovsky M: Localization of phencyclidine binding sites on alpha and beta subunits of the nicotonic acetylcholine receptor from Torpedo ocellata electric organ using azido phencyclidine. J Neurochem 4: 627–637, 1984
Quirion R, Bayorh MA, Zerbe RL, Pert CB: Chronic phencyclidine treatment decreases phencyclidine and dopamine receptors in rat brain. Pharmacol Biochem Behav 17: 699–702, 1982
Gao XM, Tamminga CA: Phencyclidine produces changes in NMDA and kainate receptor binding in rat hippocampus over a 48 h time course. Synapse 23: 274–279, 1996
Debonnel G, deMontigny C: Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: Possible implications for the treatment of psychiatric disorders. Life Sci 58: 721–734, 1996
Itoh Y, Oishi R, Nishibori M, Saeki K: Phencyclidine and the dynamics of mouse brain histamine. J Pharmacol Exp Ther 235: 788–792, 1985
Nabeshima T, Sivam SP, Norris JC, Ho IK: Calcium-dependent GABA release from mouse brain slices following acute and chronic phencyclidine administration. Res Comm Subst Abuse 2: 343–354, 1981
Ary TE, Komiskey HL: Phencyclidine induced release of [3H] dopamine from chopped striatal tissue. Neuropharmacol 21: 639–645, 1982
Nabeshima T, Yamaguchi K, Hiramatsu M, Amano M, Pumkawa I, Kanneyama T: Serotonergic involvement in phencyclidine-induced behaviors. Pharmacol Biochem Behav 21: 401–408, 1984
Bowyer JR, Spuhler KP, Weiner N: Effects of phencyclidine, amphetamine and related compounds in dopamine release from striatal slices. J Pharmacol Exp Ther 257: 262–270, 1984
Ali SF, Holson RR, Newport ED, Slikker W Jr, Bowyer JF: Development of dopamine and N-methyl-D-aspartate systems in rat brain: The effect of prenatal phencyclidine exposure. Dev Brain Res 73: 25–33, 1993
Corso TD, Sesma MA, Tenkova TI, Der TC, Wozniak DF, Farber NB, Olney JW: Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res 752: 1–14, 1997
Rasmussen H, Barrett PG: Calcium messenger system: An integrated view. Physiol Rev 64: 938–984, 1984
Komulainen H, Bondy SC: Modulation of levels of free calcium within synaptosomes by organochlorine insecticides. J Pharmacol Exp Ther 241: 575–581, 1987
Carafoli E: Intracellular calcium homeostasis. Ann Rev Biochem 56: 395–433, 1987
Kodavanti PRS, Pentyala SN, Yallapragada PR, Desaiah D: Amiodarone and desethylamiodarone increase intrasynaptosomal free calcium through receptor mediated channel. Arch Pharmacol 345: 213–221, 1992
Enna SJ, Snyder SH: Influence of ions, enzymes, and detergents on γ-amiobutyric acid receptor binding in synaptic membranes of rat brain. Mol Pharmacol 13: 442–453, 1977
Yallagragada PR, Vig PJS, Desaiah D: Differential effects of triorganotins on calmodulin activity. J Toxicol Env Health 29: 317–327, 1990
Lowry OH, Lopez JA: The determination of inorganic phosphate in the presence of labile phosphate esters. J Biol Chem 162: 421–424, 1946
Cooper JE, Cummings AJ, Jones H: The placental transfer of phencyclidine in the pig: Plasma levels in the sow and its piglets. J Physiol 267: 17–26, 1977
Strauss A, Modanlou HD, Bosu SK: Neonatal manifestations of maternal phencyclidine abuse. Pediatrics 68: 550–552, 1981
Ahmad G, Halsall LC, Bondy SC: Persistence of phencyclidine in fetal brain. Brain Res 415: 194–196, 1987
Sircar R, Li CS: PCP/NMDA receptor-channel complex and brain development. Neurotoxicol Teratol 16: 369–375, 1994
Sircar R, Follesa P, Ticku MK: Postnatal phencyclidine treatment differentially regulates N-methyl-D-Aspartate receptor subunit mRNA expression in developing rat cerebral cortex. Mol Brain Res 40: 214–220, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pande, M., Cameron, J., Vig, P. et al. Inhibition of calcium ATPase by phencyclidine in rat brain. Mol Cell Biochem 194, 173–177 (1999). https://doi.org/10.1023/A:1006911420745
Issue Date:
DOI: https://doi.org/10.1023/A:1006911420745